ELUT

+ Watchlist + Portfolio

Elutia, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.92
52-Week Range: $0.50 – $2.50
Market Cap: $39.94M
P/E (TTM): —
EPS (TTM): -0.63
Dividend Yield: —

Advanced Metrics

Price/Book: 2.53
PEG Ratio: —
Return on Equity: —
Return on Assets: -34.66%
Gross Margin: 57.76%
Operating Margin: -243.10%
Profit Margin: 426.90%
Current Ratio: 1.77
Debt/Equity: 0.28
Total Debt: $4.38M
Free Cash Flow: $-27.47M
Revenue Growth: -11.60%
Earnings Growth: —
Enterprise Value: $24.42M

ELUT Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$23.85M	$24.75M	$14.47M	$12.29M
Cost of Revenue	$12.21M	$13.69M	$7.75M	$5.70M
Gross Profit	$11.64M	$11.05M	$6.71M	$6.60M
Research & Development	$7.73M	$4.40M	$3.00M	$4.16M
Selling, General & Admin	$33.90M	$27.19M	$23.06M	$20.84M
Operating Expenses	$41.63M	$31.59M	$26.06M	$25.01M
Operating Income	-$29.99M	-$20.54M	-$19.34M	-$18.41M
EBITDA	-$27.30M	-$31.68M	-$40.99M	-$15.63M
Pretax Income	-$36.15M	-$41.22M	-$45.34M	-$15.86M
Income Tax	$34.00K	$28.00K	$7.00K	$13.00K
Net Income	-$32.90M	-$37.66M	-$53.95M	$53.38M
Diluted EPS	-2.38	-2.07	-1.86	0.87
Diluted Shares	13.83M	18.16M	29.07M	45.94M

ELUT Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$16.99M	$19.28M	$13.24M	$36.35M
Receivables	$17.59M	$5.96M	$7.04M	$14.58M
Inventory	$4.24M	$3.85M	$1.93M	$2.62M
Current Assets	$50.70M	$31.25M	$26.17M	$55.82M
Total Assets	$68.84M	$43.43M	$36.13M	$62.35M
Current Liabilities	$42.62M	$43.04M	$37.80M	$25.14M
Long-Term Debt	$24.26M	$20.36M	$22.60M	—
Total Debt	$24.49M	$23.95M	$24.01M	$3.94M
Total Liabilities	$73.87M	$82.03M	$82.39M	$34.68M
Retained Earnings	-$137.99M	-$175.64M	-$229.59M	-$176.21M
Shareholders' Equity	-$5.03M	-$38.60M	-$46.26M	$27.67M
Working Capital	$8.08M	-$11.78M	-$11.62M	$30.68M
Net Debt	$7.27M	$4.40M	$10.61M	—

ELUT Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$21.43M	-$21.76M	-$22.66M	-$44.81M
Capital Expenditure	-$540.00K	-$346.00K	-$654.00K	-$1.88M
Free Cash Flow	-$21.97M	-$22.11M	-$23.31M	-$46.69M
Depreciation & Amortisation	$3.73M	$3.75M	$3.45M	$2.79M
Stock-Based Compensation	$3.65M	$2.44M	$7.89M	$5.21M
Investing Cash Flow	-$540.00K	$14.21M	-$474.00K	$78.56M
Financing Cash Flow	$8.54M	$9.84M	$17.09M	-$10.64M
Net Change in Cash	-$13.44M	$2.29M	-$6.04M	$23.11M

ELUT Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$2.95M	$6.26M	$3.32M	$3.27M	$3.11M
Cost of Revenue	$1.57M	$3.21M	$1.47M	$1.36M	$1.31M
Gross Profit	$1.38M	$3.06M	$1.85M	$1.91M	$1.80M
Research & Development	$871.00K	$1.46M	$1.09M	$1.22M	$1.97M
Selling, General & Admin	$4.72M	$7.47M	$5.12M	$6.19M	$5.57M
Operating Expenses	$5.59M	$8.93M	$6.21M	$7.41M	$7.54M
Operating Income	-$4.21M	-$5.87M	-$4.36M	-$5.49M	-$5.74M
EBITDA	-$827.00K	-$8.19M	$618.00K	-$5.19M	-$5.41M
Pretax Income	-$1.88M	-$9.60M	-$375.00K	-$6.52M	-$7.82M
Income Tax	$8.00K	$8.00K	$8.00K	-$11.00K	$70.00K
Net Income	-$3.93M	-$9.61M	-$3.87M	$70.79M	-$7.47M
Diluted EPS	-0.21	-0.26	-0.19	1.48	-0.17
Diluted Shares	42.91M	46.31M	46.96M	47.24M	43.00M

ELUT Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$17.36M	$8.50M	$4.72M	$36.35M	$28.49M
Receivables	$6.75M	$7.45M	$8.11M	$14.58M	$15.42M
Inventory	$4.29M	$5.24M	$2.01M	$2.62M	$2.66M
Current Assets	$30.02M	$22.28M	$18.38M	$55.82M	$48.59M
Total Assets	$39.30M	$33.85M	$29.41M	$62.35M	$55.21M
Current Liabilities	$36.85M	$37.95M	$41.33M	$25.14M	$23.73M
Long-Term Debt	$21.76M	$21.37M	$21.10M	—	—
Total Debt	$25.02M	$28.24M	$29.14M	$3.94M	$4.22M
Total Liabilities	$75.76M	$75.69M	$73.33M	$34.68M	$32.68M
Retained Earnings	-$233.53M	-$243.14M	-$247.00M	-$176.21M	-$183.68M
Shareholders' Equity	-$36.46M	-$41.84M	-$43.92M	$27.67M	$22.53M
Working Capital	-$6.83M	-$15.67M	-$22.96M	$30.68M	$24.87M
Net Debt	$6.90M	$16.62M	$21.38M	—	—

ELUT Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$8.88M	-$8.23M	-$2.89M	-$24.81M	-$7.83M
Capital Expenditure	-$278.00K	-$114.00K	-$630.00K	-$854.00K	-$459.00K
Free Cash Flow	-$9.16M	-$8.34M	-$3.52M	-$25.67M	-$8.29M
Depreciation & Amortisation	$868.00K	$892.00K	$728.00K	$297.00K	$330.00K
Stock-Based Compensation	$1.21M	$1.15M	$1.98M	$872.00K	$931.00K
Investing Cash Flow	-$278.00K	-$114.00K	-$630.00K	$79.58M	-$34.00K
Financing Cash Flow	$13.28M	-$516.00K	-$262.00K	-$23.14M	$3.00K
Net Change in Cash	$4.12M	-$8.86M	-$3.78M	$31.63M	-$7.86M

Market Snapshot

About

Elutia Inc. is a commercial-stage company focused on developing and commercializing regenerative medicine products. The company's technology platform is based on extracellular matrix biomaterials that support tissue repair and regeneration. Elutia markets products for surgical applications including hernia repair, soft tissue reconstruction, and wound care. The company's portfolio includes both resorbable and non-resorbable biomaterial solutions designed to integrate with the body's natural healing processes.